eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2020
vol. 71
 
Share:
Share:
more
 
 
abstract:
Original paper

PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population

Łukasz Szylberg
1, 2
,
Ewa Antoniewicz
3
,
Wojciech Olszewski
4
,
Adam Kowalewski
1, 2
,
Marek Zdrenka
1
,
Beata Dziekan
3
,
Matthew Ibbs
3
,
Violetta Filas
3
,
Andrzej Marszałek
3

1.
Department of Tumor Pathology and Pathomorphology, Oncology Center, Prof. Franciszek £ukaszczyk Memorial Hospital, Bydgoszcz, Poland
2.
Chair of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
3.
Chair and Department of Oncologic Pathology and Prophylaxis, Greater Poland Cancer Center, Poznañ University of Medical Sciences and Department of Oncologic Pathology, Poznan, Poland
4.
Department of Pathology, Maria Sk³odowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
Pol J Pathol 2020; 71 (4): 301-306
Online publish date: 2021/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast carcinomas and represents an aggressive variant with a high mortality rate. PD-L1 is a protein that plays a pivotal role in suppressing the adaptive immune system. It has become a central target of the immunotherapy approach. Determining the PD-L1 status can identify TNBC patients who may benefit from targeted therapy. This study was performed to estimate the prevalence of PD-L1 expression among Polish TNBC patients. A total of 123 patients with TNBC were tested for PD-L1 expression using immunohistochemical studies. The PD-L1-positive tumors were found in 55 patients (45%), while PD-L1-negative tumors were found in 68 patients (55%). The PD-L1 positive tumors included 17 patients (31%) with the expression covering up to 1% of tumor area, 23 patients (42%) covering 2-5%, 8 patients (14%) covering 6-10% and 7 patients (13%) covering more than 10% of tumor area. The PD-L1 negative tumors included 17 patients (25%) with the expression covering less than 1% of tumor area and 51 patients (75%) with a complete lack of expression. There were no significant differences between the groups with different status of PD-L1 and the clinical tumor and lymph node stages as well as the patients’ age.
keywords:

TNBC, PD-L1, breast cancer, triple negative

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe